DataMeds AI has entered into an exclusive IP license agreement with REBOOT Health AI for its platform to manage GLP-1 users in the US direct-to-consumer market. This deal involves DataMeds issuing 666,667 shares to REBOOT, with a potential for additional shares if the market value falls below $2 million, and a revenue-sharing agreement, indicating a strategic move into a growing healthcare segment.
DataMeds AI has secured an exclusive license to REBOOT Health AI's platform for managing GLP-1 users in the US direct-to-consumer market. This is a significant strategic move for DataMeds, allowing them to leverage advanced AI in a rapidly expanding healthcare niche. The deal involves DataMeds issuing 666,667 shares to REBOOT, with a potential true-up mechanism if the share value drops below $2 million, which could lead to further dilution for DataMeds shareholders. Additionally, REBOOT will receive a portion of DataMeds' adjusted gross revenue, creating a long-term financial tie. For DataMeds, this represents an opportunity for growth and market penetration, but also a financial commitment through equity issuance and revenue sharing. For REBOOT, it's a monetization of their IP and platform, with upside potential tied to DataMeds' success. Traders should monitor DataMeds' stock performance, especially around the 180-day mark, for potential additional share issuance and its impact on dilution.